Serum Markers of Neurodegeneration Are Strongly Linked to Heart Failure Severity and Outcome

JACC Heart Fail. 2024 Jun;12(6):1073-1085. doi: 10.1016/j.jchf.2024.03.005.

Abstract

Background: Cognitive impairment is prevalent in patients with heart failure with reduced ejection fraction (HFrEF), affecting self-care and outcomes. Novel blood-based biomarkers have emerged as potential diagnostic tools for neurodegeneration.

Objectives: This study aimed to assess neurodegeneration in HFrEF by measuring neurofilament light chain (NfL), total tau (t-tau), amyloid beta 40 (Aβ40), and amyloid beta 42 (Aβ42) in a large, well-characterized cohort.

Methods: The study included 470 patients with HFrEF from a biobank-linked prospective registry at the Medical University of Vienna. High-sensitivity single-molecule assays were used for measurement. Unplanned heart failure (HF) hospitalization and all-cause death were recorded as outcome parameters.

Results: All markers, but not the Aβ42:Aβ40 ratio, correlated with HF severity, ie, N-terminal pro-B-type natriuretic peptide and NYHA functional class, and comorbidity burden and were significantly associated with all-cause death and HF hospitalization (crude HR: all-cause death: NfL: 4.44 [95% CI: 3.02-6.53], t-tau: 5.04 [95% CI: 2.97-8.58], Aβ40: 3.90 [95% CI: 2.27-6.72], and Aβ42: 5.14 [95% CI: 2.84-9.32]; HF hospitalization: NfL: 2.48 [95% CI: 1.60-3.85], t-tau: 3.44 [95% CI: 1.95-6.04], Aβ40: 3.13 [95% CI: 1.84-5.34], and Aβ42: 3.48 [95% CI: 1.93-6.27]; P < 0.001 for all). These associations remained statistically significant after multivariate adjustment including N-terminal pro-B-type natriuretic peptide. The discriminatory accuracy of NfL in predicting all-cause mortality was comparable to the well-established risk marker N-terminal pro-B-type natriuretic peptide (C-index: 0.70 vs 0.72; P = 0.225), whereas the C-indices of t-tau, Aβ40, Aβ42, and the Aβ42:Aβ40 ratio were significantly lower (P < 0.05 for all).

Conclusions: Neurodegeneration is directly interwoven with the progression of HF. Biomarkers of neurodegeneration, particularly NfL, may help identify patients potentially profiting from a comprehensive neurological work-up. Further research is necessary to test whether early diagnosis or optimized HFrEF treatment can preserve cognitive function.

Keywords: cardiocerebral syndrome; cognitive impairment; heart failure; neurodegeneration; neurofilament light chain.

MeSH terms

  • Aged
  • Amyloid beta-Peptides* / blood
  • Biomarkers* / blood
  • Cognitive Dysfunction / blood
  • Cognitive Dysfunction / diagnosis
  • Female
  • Heart Failure* / blood
  • Heart Failure* / diagnosis
  • Heart Failure* / mortality
  • Hospitalization / statistics & numerical data
  • Humans
  • Male
  • Middle Aged
  • Natriuretic Peptide, Brain / blood
  • Neurodegenerative Diseases / blood
  • Neurodegenerative Diseases / diagnosis
  • Neurofilament Proteins* / blood
  • Peptide Fragments* / blood
  • Prospective Studies
  • Severity of Illness Index*
  • Stroke Volume / physiology
  • tau Proteins* / blood

Substances

  • Biomarkers
  • Amyloid beta-Peptides
  • Peptide Fragments
  • tau Proteins
  • Neurofilament Proteins
  • neurofilament protein L
  • Natriuretic Peptide, Brain
  • pro-brain natriuretic peptide (1-76)
  • amyloid beta-protein (1-42)
  • amyloid beta-protein (1-40)